CA3174709A1 - Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy - Google Patents

Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Info

Publication number
CA3174709A1
CA3174709A1 CA3174709A CA3174709A CA3174709A1 CA 3174709 A1 CA3174709 A1 CA 3174709A1 CA 3174709 A CA3174709 A CA 3174709A CA 3174709 A CA3174709 A CA 3174709A CA 3174709 A1 CA3174709 A1 CA 3174709A1
Authority
CA
Canada
Prior art keywords
tetrafluoro
trifluoromethylbenzylamino
compound
therapy
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174709A
Other languages
English (en)
French (fr)
Inventor
Byoung Joo Gwag
Chun San An
Jing Yu JIN
Sung Ig Cho
Fangmeng ZHU
Xinliang XU
Weiqiang Zhan
Fuxin LIU
Soon-Mi WON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GNT Pharma Co Ltd
Original Assignee
GNT Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GNT Pharma Co Ltd filed Critical GNT Pharma Co Ltd
Publication of CA3174709A1 publication Critical patent/CA3174709A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3174709A 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy Pending CA3174709A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
US62/988,187 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (1)

Publication Number Publication Date
CA3174709A1 true CA3174709A1 (en) 2021-09-16

Family

ID=77665492

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174709A Pending CA3174709A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL296288B2 (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309703C (zh) * 2002-06-19 2007-04-11 纽若泰克有限公司 四氟苄基衍生物及含有其成分的用于治疗和预防中枢神经系统的急慢性神经变性疾病的药物组合物
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
WO2006126825A1 (en) 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CN101180263B (zh) 2005-05-25 2011-11-02 株式会社中外制药 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
KR101523345B1 (ko) 2008-04-28 2015-05-28 주식회사 지엔티파마 재관류 손상의 치료 또는 예방용 약학 조성물
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Also Published As

Publication number Publication date
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
US12433861B2 (en) 2025-10-07
KR20230010187A (ko) 2023-01-18
IL296288B1 (en) 2024-02-01
US20260027076A1 (en) 2026-01-29
US20230390231A1 (en) 2023-12-07
JP2023517566A (ja) 2023-04-26
US20210283080A1 (en) 2021-09-16
IL309923A (en) 2024-03-01
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
WO2021181159A1 (en) 2021-09-16
BR112022018136A2 (pt) 2022-10-25
MX2022011214A (es) 2022-10-07
CO2022014343A2 (es) 2023-02-16
AU2021233206A1 (en) 2022-10-06
CN115515573A (zh) 2022-12-23
IL296288B2 (en) 2024-06-01
MX2025012439A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
US12433861B2 (en) Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
EP3013335B1 (en) Combination therapy for the treatment of cancer comprising eribulin and lenvatinib
KR101738201B1 (ko) 구토방지제로서의 아미설프라이드의 용도
US20230149372A1 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
ES2249707T3 (es) Tratameinto de combinacion para infarto de miocardio agudo.
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
BR122025026201A2 (pt) Composições que compreendem o composto derivado de tetrafluorobenzila, frascos compreendendo as mesmas, uso terapêutico das mesmas e método para preparar o referido composto
CN117412751A (zh) 用于预防或治疗肺纤维化的药物制剂
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
EP4139308B1 (en) Purine derivatives as drugs for the treatment of neonatal hypoxia-ischemia brain injury and related diseases
WO2016047662A1 (ja) 脳卒中の治療剤
KR20250106246A (ko) 테트라플루오로벤질 유도체와 저체온 병용치료로 뇌 손상, 장애, 및/또는 사망을 줄이기 위한 조성물 및 방법
KR101768809B1 (ko) 덱사메타손 및 글리벤클라마이드를 포함하는 뇌졸중의 예방 또는 치료용 약학적 조성물
JP2012136478A (ja) 骨壊死予防及び／又は治療剤
WO2022089544A1 (zh) Bzp在治疗心脑缺血性疾病中的应用
KR20060120204A (ko) 삼출성 중이염의 예방 및/또는 치료제
JPH0369324B2 (https=)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240924

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240924

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240930

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250321

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250326

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251211